Press Release

Extreme Labs Selects IP Infusion OcNOS® for Secure Connectivity Between Data Centers

IP Infusion Expands its Footprint in India by Supporting the Country's Largest Internet Exchange 

 

SANTA CLARA, Calif. Oct. 24, 2022 IP Infusion, a leading provider of open network software solutions for wireline and mobile network operators, announced today that Extreme Labs, a leading Internet Exchange Point (IXP) focused on Internet optimization, has chosen IP Infusion's OcNOS® to diversify and strengthen its network disaggregation strategy. IP Infusion's software, running on Edgecore's aggregation hardware, is now an integral part of the Extreme Labs infrastructure, supporting a more agile, cost-effective connectivity while increasing security.

 

Extreme Labs operates the largest Internet Exchange in India, Extreme IX™, for more than 35 data centers across six major regions of the country. Distribution partner, EPS Global, worked with IP Infusion to coordinate the platform strategy for entering the country and enabled Extreme Labs' migration to OcNOS.

 

Focusing on Layer 2 connectivity, Extreme Labs' fabric architecture brings high efficiency and low latency to the network by reducing the distance between endpoints. IP Infusion's OcNOS solution enables Extreme Labs to deploy advanced connectivity features including Virtual Extensible LAN (VxLAN) for scalability and resiliency, as well as hardened security protocols that provide strong and restricted port security, traffic shaping and DDoS-protection storm control.

 

"As we explored best practices for diversifying Extreme Labs' options, we found IP Infusion to be an excellent fit," said Ahmed Musaddaq Al-Saruri, Senior Network Architect of Extreme Labs. "Throughout the rigorous testing and analysis processes, it quickly became apparent that IP Infusion's interface offered the ease of provisioning we require. IP Infusion's solution reliably supports our network for advanced features we currently have in our infrastructure, with excellent customer support, while also positioning us for future features."

 

"IP Infusion's OcNOS was selected for its modular and open structure that freed Extreme Labs from vendor lock-in to deliver a seamless migration towards its goal of total network disaggregation," said Atsushi Ogata, President and CEO of IP Infusion. "This open architecture encourages innovation and faster time to market with new services."

 

IP Infusion について

 

IP Infusion is a leading provider of open network software and solutions for carriers, service providers and data center operators with more than 500 customers and thousands of deployments. Our solutions enable network operators to disaggregate their networks to accelerate innovation, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier grade robustness.

 

IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.

 

IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.

 

-end-

 

Media Contacts

 

For IP Infusion:

 

Katherine Verducci

1903 PR

kverducci@1903pr.com

408.429.5779

IP Infusion について

IP Infusion はオープンネットワーキングソフトウェアの主要プロバイダーであり、サービスプロバイダー、データセンター、AI ファブリックネットワーク向けのキャリアグレードネットワーク OS である OcNOS を提供しています。26+ 年のネットワーク技術の知見と世界 600+ のオペレーターでの実績により、Edgecore Networks、UfiSpace、Celestica などのパートナーによる検証済みオープンハードウェア上で、オープンかつマルチベンダーで、コスト効率が高く柔軟なネットワークインフラを実現します。IP Infusion は株式会社 ACCESS(東京証券取引所: 4813)の完全子会社です。

メディア窓口

For press inquiries, analyst briefings, or media materials, please チームへお問い合わせ or email pr@ipinfusion.com.

将来見通しに関する記述

本リリースには、IP Infusion の製品、技術および計画に関する将来見通しの記述が含まれる場合があります。将来見通しに関する記述は公表日時点で入手可能な情報に基づいており、リスクと不確実性を伴います。実際の結果は異なる可能性があります。製品計画、機能、リリース時期および提供状況は予告なく変更されることがあり、確約、約束または法的義務を構成するものではありません。IP Infusion は将来見通しに関する記述を更新する義務を負いません。